CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.32
9.02%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-0.26)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.04)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

FibroGen Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.55
Open* 2.49
1-Year Change* -86.66%
Day's Range* 2.31 - 2.51
52 wk Range 0.33-25.69
Average Volume (10 days) 1.11M
Average Volume (3 months) 35.86M
Market Cap 78.16M
P/E Ratio -100.00K
Shares Outstanding 98.34M
Revenue 154.98M
EPS -3.06
Dividend (Yield %) N/A
Beta 0.67
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 2.32 -0.20 -7.94% 2.52 2.56 2.29
Mar 27, 2024 2.55 0.15 6.25% 2.40 2.65 2.29
Mar 26, 2024 2.42 -0.20 -7.63% 2.62 2.76 2.39
Mar 25, 2024 2.62 0.07 2.75% 2.55 2.76 2.51
Mar 22, 2024 2.56 0.17 7.11% 2.39 2.64 2.34
Mar 21, 2024 2.41 0.10 4.33% 2.31 2.46 2.29
Mar 20, 2024 2.33 0.10 4.48% 2.23 2.37 2.13
Mar 19, 2024 2.33 0.10 4.48% 2.23 2.37 2.11
Mar 18, 2024 2.15 0.06 2.87% 2.09 2.35 1.93
Mar 15, 2024 2.07 0.06 2.99% 2.01 2.18 1.99
Mar 14, 2024 2.08 0.10 5.05% 1.98 2.14 1.90
Mar 13, 2024 1.99 0.13 6.99% 1.86 2.15 1.83
Mar 12, 2024 1.87 0.15 8.72% 1.72 2.04 1.72
Mar 11, 2024 1.68 -0.03 -1.75% 1.71 1.81 1.67
Mar 8, 2024 1.78 0.00 0.00% 1.78 1.86 1.73
Mar 7, 2024 1.77 -0.04 -2.21% 1.81 1.88 1.69
Mar 6, 2024 1.84 -0.03 -1.60% 1.87 1.93 1.82
Mar 5, 2024 1.91 0.05 2.69% 1.86 1.94 1.76
Mar 4, 2024 1.95 0.16 8.94% 1.79 1.99 1.75
Mar 1, 2024 1.80 0.06 3.45% 1.74 1.87 1.67

FibroGen, Inc Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 FibroGen Inc Earnings Release
Q1 2024 FibroGen Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 6, 2024

Time (UTC)

15:00

Country

US

Event

FibroGen Inc Annual Shareholders Meeting
FibroGen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 140.734 235.309 176.319 256.577 212.958
Revenue 140.734 235.309 176.319 256.577 212.958
Total Operating Expense 441.759 523.839 368.199 345.891 299.651
Selling/General/Admin. Expenses, Total 127.474 120.557 97.238 126.557 63.812
Research & Development 296.791 387.043 252.924 209.265 235.839
Operating Income -301.025 -288.53 -191.88 -89.314 -86.693
Interest Income (Expense), Net Non-Operating 6.156 -2.153 3.151 12.672 0.577
Net Income Before Taxes -294.869 -290.683 -188.729 -76.642 -86.116
Net Income After Taxes -295.227 -291.03 -189.089 -76.97 -86.42
Net Income Before Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Net Income -293.654 -290.023 -189.291 -76.97 -86.42
Income Available to Common Excl. Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Income Available to Common Incl. Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Diluted Net Income -293.654 -290.023 -189.291 -76.97 -86.42
Diluted Weighted Average Shares 93.582 92.349 89.854 86.633 84.062
Diluted EPS Excluding Extraordinary Items -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Diluted Normalized EPS -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Total Extraordinary Items
Cost of Revenue, Total 20.28 12.871 8.869 1.147
Gross Profit 120.454 222.438 167.45 255.43
Depreciation / Amortization 0.587 4.639 10.369 10.307
Other Operating Expenses, Total -3.373 -1.271 -1.201 -1.385
Equity In Affiliates 1.573 1.007 -0.202
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 44.319 36.161 34.367 15.735 29.806
Revenue 44.319 36.161 34.367 15.735 29.806
Cost of Revenue, Total 5.708 3.491 4.925 4.308 6.809
Gross Profit 38.611 32.67 29.442 11.427 22.997
Total Operating Expense 132.367 112.252 100.519 109.392 108.03
Selling/General/Admin. Expenses, Total 31.181 34.275 33.966 29.902 30.258
Research & Development 95.478 74.486 61.628 75.182 70.963
Other Operating Expenses, Total
Operating Income -88.048 -76.091 -66.152 -93.657 -78.224
Interest Income (Expense), Net Non-Operating -0.417 -1.336 -0.195 1.714 5.058
Net Income Before Taxes -88.465 -77.427 -66.347 -91.943 -73.166
Net Income After Taxes -88.23 -77.501 -66.455 -92.057 -73.189
Equity In Affiliates 0.55 0.796 0.28 0.407 0.565
Net Income Before Extra. Items -87.68 -76.705 -66.175 -91.65 -72.624
Net Income -87.68 -76.705 -66.175 -91.65 -72.624
Income Available to Common Excl. Extra. Items -87.68 -76.705 -66.175 -91.65 -72.624
Income Available to Common Incl. Extra. Items -87.68 -76.705 -66.175 -91.65 -72.624
Diluted Net Income -87.68 -76.705 -66.175 -91.65 -72.624
Diluted Weighted Average Shares 97.729 94.691 94.035 93.767 93.475
Diluted EPS Excluding Extraordinary Items -0.89717 -0.81006 -0.70373 -0.97742 -0.77694
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.89717 -0.81006 -0.70373 -0.97742 -0.77694
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 492.826 474.059 755.11 702.49 690.015
Cash and Short Term Investments 422.008 405.19 686.537 533.757 621.402
Cash 135.819 111.422 88.046 40.715 38.783
Cash & Equivalents 19.881 59.801 590.347 85.551 50.475
Short Term Investments 266.308 233.967 8.144 407.491 532.144
Total Receivables, Net 16.299 25.401 41.883 153.665 63.684
Accounts Receivable - Trade, Net 28.387 36.331 46.01 158.51 16.474
Prepaid Expenses 9.73 7.383 8.353 6.464 4.929
Total Assets 610.087 773.821 826.84 857.397 880.598
Property/Plant/Equipment, Total - Net 100.933 120.15 65.296 84.276 127.198
Property/Plant/Equipment, Total - Gross 253.644 252.362 199.305 195.752 192.397
Accumulated Depreciation, Total -152.711 -132.212 -134.009 -111.476 -65.199
Long Term Investments 9.409 171.621 2.972 61.118 55.82
Other Long Term Assets, Total 6.919 7.991 3.462 9.513 7.565
Total Current Liabilities 273.562 225.497 163.187 102.745 89.033
Accounts Payable 30.758 26.097 24.789 6.088 9.139
Accrued Expenses 229.639 180.356 104.384 83.816 66.123
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 13.129 19.033 21.684 0.49 13.771
Total Liabilities 631.534 564.675 404.662 341.262 371.399
Total Long Term Debt 17.054 17.616 44.088 55.531 113.955
Long Term Debt 16.917 17.613 18.697 16.78 16.798
Capital Lease Obligations 0.137 0.003 25.391 38.751 97.157
Minority Interest 19.967 19.967 19.271 19.271 19.271
Other Liabilities, Total 320.951 292.403 169.441 163.715 149.14
Total Equity -21.447 209.146 422.178 516.135 509.199
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.942 0.929 0.914 0.877 0.854
Additional Paid-In Capital 1541.02 1476.41 1399.77 1300.72 1226.45
Retained Earnings (Accumulated Deficit) -1557.69 -1264.03 -974.011 -784.72 -715.827
Other Equity, Total -5.72 -4.163 -4.499 -0.747 -2.281
Total Liabilities & Shareholders’ Equity 610.087 773.821 826.84 857.397 880.598
Total Common Shares Outstanding 94.1661 92.881 91.441 87.657 85.432
Total Inventory 40.436 31.015 16.53 6.887
Other Current Assets, Total 4.353 5.07 1.807 1.717
Current Port. of LT Debt/Capital Leases 0.036 0.011 12.33 12.351
Deferred Income Tax 9.192 8.675
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 364.108 411.357 430.549 492.826 474.224
Cash and Short Term Investments 251.34 335.716 355.949 422.008 408.52
Cash 70.982 81.727 145.81 135.819 104.509
Cash & Equivalents 49.932 70.858 42.74 19.881 51.451
Short Term Investments 130.426 183.131 167.399 266.308 252.56
Total Receivables, Net 31.694 25.599 17.654 16.299 15.328
Accounts Receivable - Trade, Net 54.61 45.55 29.217 28.387 29.665
Total Inventory 40.696 41.179 42.456 40.436 39.95
Prepaid Expenses 40.378 8.863 14.49 9.73 10.426
Other Current Assets, Total 4.353
Total Assets 460.426 515.127 538.544 610.087 608.837
Property/Plant/Equipment, Total - Net 85.76 91.233 95.367 100.933 105.19
Property/Plant/Equipment, Total - Gross 253.644
Accumulated Depreciation, Total -152.711
Long Term Investments 4.534 6.112 5.884 9.409 22.411
Other Long Term Assets, Total 6.024 6.425 6.744 6.919 7.012
Total Current Liabilities 209.415 194.072 254.746 273.562 251.994
Accounts Payable 19.22 12.802 71.282 30.758 19.323
Accrued Expenses 182.87 173.78 166.969 229.639 224.577
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.036
Other Current Liabilities, Total 7.325 7.49 16.495 13.129 8.094
Total Liabilities 617.595 617.401 587.396 631.534 582.531
Total Long Term Debt 88.608 88.773 17.276 17.054 15.422
Long Term Debt 88.608 88.773 17.276 16.917 15.422
Capital Lease Obligations 0.137
Deferred Income Tax
Minority Interest 41.967 41.967 19.967 19.967 19.967
Other Liabilities, Total 277.605 292.589 295.407 320.951 295.148
Total Equity -157.169 -102.274 -48.852 -21.447 26.306
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.983 0.982 0.966 0.942 0.939
Additional Paid-In Capital 1634.46 1625.07 1589.15 1541.02 1524.23
Retained Earnings (Accumulated Deficit) -1785.69 -1722.07 -1634.39 -1557.69 -1491.51
Other Equity, Total -6.923 -6.25 -4.57 -5.72 -7.346
Total Liabilities & Shareholders’ Equity 460.426 515.127 538.544 610.087 608.837
Total Common Shares Outstanding 98.3391 98.2042 96.623 94.1661 93.936
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -293.654 -290.023 -189.291 -76.97 -86.42
Cash From Operating Activities -145.933 -82.232 81.602 -78.705 -76.144
Cash From Operating Activities 10.604 14.809 22.047 21.454 6.562
Non-Cash Items 66.687 132.899 74.216 62.47 52.112
Cash Interest Paid 0.104 0.094 0.135 0.174 0.218
Changes in Working Capital 70.43 60.083 174.63 -85.659 -48.398
Cash From Investing Activities 89.116 -426.972 452.487 120.018 -522.123
Capital Expenditures -38.741 -30.186 -3.994 -5.762 -8.02
Other Investing Cash Flow Items, Total 127.857 -396.786 456.481 125.78 -514.103
Cash From Financing Activities 46.776 -0.563 13.343 -4.3 13.875
Financing Cash Flow Items -6.62 -7.372 -11.463 -12.75 -15.612
Issuance (Retirement) of Stock, Net 53.934 12.701 37.829 20.778 29.847
Issuance (Retirement) of Debt, Net -0.538 -5.892 -13.023 -12.328 -0.36
Foreign Exchange Effects -5.482 2.597 4.695 -0.005 -0.008
Net Change in Cash -15.523 -507.17 552.127 37.008 -584.4
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -76.705 -293.654 -227.479 -135.829 -63.205
Cash From Operating Activities -101.591 -145.933 -93.42 -41.54 -8.476
Cash From Operating Activities 2.965 10.604 7.914 5.235 2.584
Non-Cash Items 18.148 66.687 49.928 34.441 17.77
Changes in Working Capital -45.999 70.43 76.217 54.613 34.375
Cash From Investing Activities 103.482 89.116 88.023 43.24 25.935
Capital Expenditures -0.591 -38.741 -38.408 -37.543 -36.638
Other Investing Cash Flow Items, Total 104.073 127.857 126.431 80.783 62.573
Cash From Financing Activities 31.485 46.776 -1.898 -0.806 -2.893
Financing Cash Flow Items 0 -6.62 -4.562 -3.361 -2.974
Issuance (Retirement) of Stock, Net 31.657 53.934 2.989 2.779 0.183
Issuance (Retirement) of Debt, Net -0.172 -0.538 -0.325 -0.224 -0.102
Foreign Exchange Effects -0.526 -5.482 -7.968 -4.359 0.107
Net Change in Cash 32.85 -15.523 -15.263 -3.465 14.673

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

FibroGen, Inc Company profile

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

Industry: Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,295.40 Price
-0.500% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

ETH/USD

3,564.36 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading